Diagnostics
Development of PAUF-based diagnostic solutions for pancreatic cancer
Through PAUF-based diagnostic technologies that enable early detection and precision treatment, we are advancing a new paradigm in the diagnosis and management of pancreatic cancer.
Pipeline
Modality
Indiaction
Development Stage
IDC221
IHC, TASA™
PDAC
Discovery
Pipeline
IDC221
| Modality | Indiaction |
|---|---|
| IHC |
Pancreatic Cancer |
| TASA™ |
| Development Stages |
|---|
| Discovery |
Significant unmet needs in pancreatic cancer
~80% Late Diagnosis underscores the need for early detection
PAUF screening identifies high-risk patients for confirmatory biopsy and imaging
~80% Late Diagnosis underscores the need for early detection
PAUF screening identifies high-risk patients for confirmatory biopsy and imaging
~10% 5-year survival highlights the urgent need for effective therapies
PAUF-targeted treatment with ulenistamab As monotherapy or in combination, supported by clinical evidence
~10% 5-year survival highlights the urgent need for effective therapies
PAUF-targeted treatment with ulenistamab As monotherapy or in combination, supported by clinical evidence
1-year median survival in metastatic disease underscores the need for prevention
PAUF-guided prevention and surveillance Suppressing PAUF
to block tumor-promoting effects
1-year median survival in metastatic disease underscores the need for prevention
PAUF-guided prevention and surveillance Suppressing PAUF
to block tumor-promoting effects